Clinical trials
Lung Diseases, Interstitial trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 4 |
| 2020 | 2 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 8 |
| Completed | 8 |
| Active, not recruiting | 6 |
| Terminated | 5 |
| Unknown status | 3 |
| Not yet recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 8 |
| Bristol-Myers Squibb | 2 |
| Medical University of Silesia | 2 |
| AllRock Bio, Inc. | 1 |
| AstraZeneca | 1 |
| Avalyn Pharma Inc. | 1 |
| Celgene | 1 |
| Contineum Therapeutics | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Furiex Pharmaceuticals, Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Diseases, Interstitial | 32 |
| Scleroderma, Systemic | 6 |
| Pulmonary Fibrosis | 5 |
| Scleroderma, Diffuse | 5 |
| Autoimmune Diseases | 4 |
| Hypertension, Pulmonary | 4 |
| Idiopathic Pulmonary Fibrosis | 4 |
| Connective Tissue Diseases | 3 |
| Arthritis, Rheumatoid | 2 |
| Fibrosis | 2 |
Trials
Showing 51 to 32 of 32. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.